Open AccessImpact of ranolazine on ventricular arrhythmias – A systematic review
Author(s) -
Bazoukis George,
Tse Gary,
Letsas Konstantinos P.,
Thomopoulos Costas,
Naka Katerina K.,
Korantzopoulos Panagiotis,
Bazoukis Xenophon,
Michelongona Paschalia,
Papadatos Stamatis S.,
Vlachos Konstantinos,
Liu Tong,
Efremidis Michael,
Baranchuk Adrian,
Stavrakis Stavros,
Tsioufis Costas
Publication year - 2018
Publication title -
journal of arrhythmia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.463
H-Index - 21
eISSN - 1883-2148
pISSN - 1880-4276
DOI - 10.1002/joa3.12031
Subject(s) - ranolazine , medicine , observational study , ventricular tachycardia , cardiology , ventricular fibrillation , clinical trial , angina , atrial fibrillation , intensive care medicine , myocardial infarction
Ranolazine is a new medication for the treatment of refractory angina. However, except its anti‐anginal properties, it has been found to act as an anti‐arrhythmic. The aim of our systematic review is to present the existing data about the impact of ranolazine in ventricular arrhythmias. We searched MEDLINE and Cochrane databases as well clinicaltrials.gov until September 1, 2017 to find all studies (clinical trials, observational studies, case reports/series) reported data about the impact of ranolazine in ventricular arrhythmias. Our search revealed 14 studies (3 clinical trials, 2 observational studies, 8 case reports, 1 case series). These data reported a beneficial impact of ranolazine in ventricular tachycardia/fibrillation, premature ventricular beats, and ICD interventions in different clinical settings. The existing data highlight the anti‐arrhythmic properties of ranolazine in ventricular arrhythmias.